Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders

Status Completed

Clinical Trial Summary

Rationale: Chemotherapy administration before a donor stem cell transplant is necessary to stop the patient's immune system from rejecting the donor's stem cells. When healthy stem cells from a donor are infused into the patient, the donor white blood cells can provide the missing enzyme that causes the metabolic disease. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving a monoclonal antibody, alemtuzumab, before transplant and cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. This may be an effective treatment for inherited metabolic disorders.

Purpose: The design of this study is to achieve donor cell engraftment in patients with standard-risk inherited metabolic diseases with limited peri-transplant morbidity and mortality. This will be achieved through the administration of the chemotherapy regimen described. The intention is to follow transplanted patient for years after transplant monitoring them for complications of their disease and assisting families with a multifaceted interdisciplinary approach.

Clinical Trial Description

Primary Objective:

- To estimate the proportion of patients with donor derived engraftment at day 100 post transplant as defined by 80% or greater donor cells in the CD3 (T cell) fraction

Secondary Objectives:

- To determine the incidence and severity of graft-versus-host disease (GVHD) by day 100

- To determine the incidence of peri-transplant mortality (death by day 100)

- To monitor donor cell chimerism at various time points following allogeneic transplantation with this transplant regimen as determined at day 28, 42, 100, 6 months and yearly for 5 years. ;

Study Design

Related Conditions & MeSH terms

Adrenoleukodystrophy
Adrenoleukodystrophy (ALD)
Alpha Mannosidosis
alpha-Mannosidosis
Aspartylglucosaminuria
Disease
Fucosidosis
Hunter Syndrome
Hurler Syndrome
Krabbe Disease
Leukodystrophy, Globoid Cell
Leukodystrophy, Metachromatic
Maroteaux-Lamy Syndrome
Metabolic Diseases
Metachromatic Leukodystrophy (MLD)
Mucopolysaccharidoses
Mucopolysaccharidosis
Mucopolysaccharidosis I
Mucopolysaccharidosis II
Mucopolysaccharidosis VI
Mucopolysaccharidosis VII
Peroxisomal Disorders
Sly Syndrome
Sphingolipidoses
Syndrome

Clinical Trial Details

NCT number	NCT01043640
Study type	Interventional
Source	Masonic Cancer Center, University of Minnesota
Contact
Status	Completed
Phase	Phase 2
Start date	December 2009
Completion date	June 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05422482` - A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients With MPS Ⅱ	Phase 1
Completed	`NCT00630747` - Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase	Phase 2/Phase 3
Completed	`NCT03292887` - Hunter Outcome Survey (HOS)
Active, not recruiting	`NCT02455622` - Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age	Phase 4
Completed	`NCT00882921` - An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients
Completed	`NCT00920647` - A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®	Phase 1/Phase 2
Completed	`NCT01449240` - Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome
Completed	`NCT03920540` - A Study of GC1111 in Hunter Syndrom Patients	Phase 3
Recruiting	`NCT06031259` - Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment	Phase 2/Phase 3
Completed	`NCT02055118` - Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment	Phase 2/Phase 3
Completed	`NCT01645189` - Safety and Efficacy of Hunterase	Phase 3
Completed	`NCT00937794` - Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®
Recruiting	`NCT02171104` - MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis	Phase 2
Recruiting	`NCT02044692` - The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients	N/A
Completed	`NCT03582449` - Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)
Completed	`NCT01822184` - Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)
Recruiting	`NCT05494593` - A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)	Phase 4
Completed	`NCT00607386` - Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy	Phase 4
Terminated	`NCT01330277` - Biomarkers for Hunter Syndrome
Completed	`NCT01506141` - An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment	Phase 1/Phase 2